NeoGenomics (NEO) Provides 2025 Financial Guidance and Updates Long-Range Financial Plan

NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.

“We enter 2025 with our patient-centric strategy in place, focusing on product innovation, further optimization and expansion of our commercial organization, and enhancing operational efficiencies,” said Chris Smith, chief executive officer of NeoGenomics. “Building on the strong momentum of double-digit revenue growth and margin expansion we have delivered over the last few years, we are updating our Long-Range Plan and now expect revenue growth of 12-13% annually, while expanding our leadership position in oncology testing.”

2025 Financial Guidance

NeoGenomics is providing financial guidance1 for 2025. The Company expects total revenues in the range of $735 million to $745 million and adjusted EBITDA in the range of $55 million to $58 million.

With a strong cash position, we currently expect to retire the 2025 convertible notes maturing on May 1, 2025, with cash on hand.

Long-Range Growth Plan

The Long-Range Plan builds upon the successful execution of the previous three years. NeoGenomics intends to achieve the following:

• 12-13% revenue growth annually, including NGS growth of ~25% per year2
• Gross margin expansion of 100-150 bps per year
• Adjusted EBITDA improvement of 250-300 bps per year
• Positive cash flow from operations in 2025 and beyond
• Serving more than 1 million patients annually by 2028 and beyond

____________________

1 The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company’s securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.
2 Revenue growth excludes MRD

You May Also Be Interested In

• BofA Securities Upgrades Moderna (MRNA) to Neutral
• Wolverine World Wide (WWW) PT Raised to $20 at Williams Trading
• Kingsoft Cloud (KC) PT Raised to $17.70 at Jefferies